Evidence map›Paper›PMID 42469509›Full record

ArticleProstate cancer and prostatic diseases2026

Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology.

Mohamad Watfa, Kristina Dortche, Gagan Fervaha, Salim K Younis, Abdulrahman Al-Bayati, Betty Wang, Rui M Bernardino, Jesse K McKenney, Samuel Haywood, Ruben Olivares and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohamad WatfaGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0009-0003-7744-6190
Kristina DortcheGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Gagan FervahaGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Salim K YounisGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0009-0004-6596-9100
Abdulrahman Al-BayatiGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-2579-0534
Betty WangGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-1926-2468
Rui M BernardinoGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Jesse K McKenneyGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-0851-1465
Samuel HaywoodGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Ruben OlivaresGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-4895-7106
Riccardo AutorinoGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Jihad KaoukGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-7127-6069
Christopher J WeightGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Zeyad R SchwenGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Jane K NguyenGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. nguyenj@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGrade Group 1 (GG1) prostate cancer is biologically indolent and typically managed with active surveillance (AS), yet pT3a pathology is occasionally identified at radical prostatectomy (RP). Its prognostic significance in GG1 disease remains incompletely defined.

methodsRetrospective cohort of 40 patients with GG1 and pT3a disease on RP (2000-2022), confirmed on central pathologic re-review.

resultsFour patients developed biochemical recurrence (BCR); the cumulative incidence of BCR was 3.2% at 5 years and 10.3% at 15 years. No patient developed metastatic disease or prostate cancer-specific mortality.

conclusionsGG1 pT3a prostate cancer demonstrates excellent long-term outcomes. Adverse histologic features, not pathological stage alone, drive clinically meaningful risk. Late, stable PSA detectability alone does not signify meaningful recurrence.

Identifiers

PMID42469509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.